Results 21 to 30 of about 3,511 (163)
Prediction of Possible Adverse Effects of Gestational Diabetes Mellitus on Maternal and Fetal Glomeruli by Urine and Amniotic Fluid Podocyte Degradation Products [PDF]
DiagnosticsObjectives: To compare the levels of podocyte damage markers nephrin and podocalyxin in urine samples taken at the time of gestational diabetes mellitus (GDM) diagnosis and at birth.
Fatma Tanilir Cagiran +3 more
doaj +2 more sources
Scientific Reports, 2021 Podocalyxin overexpression associates with poor survival in pancreatic cancer (PDAC). We investigated whether podocalyxin expression correlates with treatment response or survival in neoadjuvant-treated PDAC.
Annika Eurola +6 more
doaj +1 more source
Podocalyxin : A Marker of Blasts in Acute Leukemia [PDF]
American Journal of Clinical Pathology, 2005 Podocalyxin is a CD34 family member expressed by podocytes, vascular endothelium, mesothelium, and a subset of hematopoietic progenitors. Podocalyxin expression was not observed in the hematopoietic cells of normal adult bone marrow samples. However, podocalyxin was expressed by blasts in 30 (77%) of 39 cases of acute myeloid leukemia (AML), 22 (81 ...
Todd W, Kelley +4 more
openaire +2 more sources
Podocalyxin in Rat Platelets and Megakaryocytes [PDF]
The American Journal of Pathology, 1999 Podocalyxin is a membrane protein of rat podocytes and endothelial cells. It has not been described in other cell types, and no amino acid or DNA sequence data are available about it. Here we show that podocalyxin antigens are present in rat platelets and megakaryocytes.
A, Miettinen +5 more
openaire +2 more sources
Podocalyxin in human haematopoietic cells [PDF]
British Journal of Haematology, 2004 SummaryPodocalyxin‐like protein (PCLP) is a sialomucin‐type membrane protein structurally related to CD34 and endoglycan. It was first described in glomerular podocytes and endothelial cells. In mice, PCLP is present in haemangioblasts, and in both chicken and mice it is a marker of early haematopoietic stem cells and lineage‐restricted haematopoietic ...
Laura, Kerosuo +5 more
openaire +2 more sources
The Role of Podocalyxin in Health and Disease [PDF]
Journal of the American Society of Nephrology, 2009 Podocalyxin, a sialomucin most closely related to CD34 and endoglycan, is expressed by kidney podocytes, hematopoietic progenitors, vascular endothelia, and a subset of neurons; aberrant expression has recently been implicated in a range of cancers.
Nielsen, J. S., McNagny, K. M.
openaire +3 more sources
Levels of serum podocalyxin in preeclampsia and relationship with maternal echocardiographic and doppler ultrasound parameters [PDF]
Folia Medica, 2022 Introduction: Podocalyxin (PCX) is an indicator of glomerular injury. Aside from the kidney, it is expressed in the endothelial cells of various organs.
Asparuh G. Nikolov +2 more
doaj +3 more sources
Urinary podocalyxin: Is it a real index of disease activity in egyptian patients lupus nephritis?
Saudi Journal of Kidney Diseases and Transplantation, 2020 Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease characterized by production of a number of antinuclear antibodies. Podocyte injury is an important feature and can be detected by several markers including podocalyxin.
Ahmed Fayed +5 more
doaj +1 more source
Podocalyxin regulates murine lung vascular permeability by altering endothelial cell adhesion. [PDF]
PLoS ONE, 2014 Despite the widespread use of CD34-family sialomucins (CD34, podocalyxin and endoglycan) as vascular endothelial cell markers, there is remarkably little known of their vascular function.
Erin J Debruin +9 more
doaj +1 more source
Advances in Biomarker Sciences and Technology, 2023 Background: Recombinant human erythropoietin (rHuEPO) is an effective treatment for renal anemia. Recently, there is evidence to suggest that rHuEPO may reduce podocyte injury in diabetic kidney disease (DKD).
Lingfeng Zeng +5 more
doaj +1 more source